DDInter1340 DDInter1826
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Omeprazole {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is associated with {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is regulated by {v} (Gene) ADGRG1
ADGRG1 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Barrett's esophagus {u} (Disease) downregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Omeprazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolazamide (Compound)
Omeprazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Omeprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide (Compound) resembles Tolazamide (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolazamide (Compound)
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolazamide (Compound)
Omeprazole (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is associated with GDF15 (Gene) and GDF15 (Gene) is downregulated by Tolazamide (Compound)
Omeprazole (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is regulated by ADGRG1 (Gene) and ADGRG1 (Gene) is downregulated by Tolazamide (Compound)
Omeprazole (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates IER3 (Gene) and IER3 (Gene) is downregulated by Tolazamide (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease) and Barrett's esophagus (Disease) downregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Tolazamide (Compound)